SCHEMBL22200788

SCHEMBL22200788

CC(C)n1c(=O)c(-c2cc(F)c(NSCc3ccc(F)cc3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 16/20 0.40
CASP1 P29466 15/20 0.40
CYP1A2 P05177 14/20 0.40
HIF1A Q16665 14/20 0.40
CASP7 P55210 13/20 0.40
TSHR P16473 8/20 0.40
CYP3A4 P08684 11/20 0.40
CYP2C9 P11712 8/20 0.40
ERN1 O75460 2/20 0.39
ALDH1A1 P00352 14/20 0.38
HSD17B10 Q99714 10/20 0.38
CYP2C19 P33261 4/20 0.38
MAPK1 P28482 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALOX15 P16050 3/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
GLA P06280 4/20 0.37
LMNA P02545 4/20 0.37
TP53 P04637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200826 0.94 ERN1 (0.39) USP2CASP1CYP1A2HIF1ACASP7
SCHEMBL22200635 0.93 ERN1 (0.39) USP2CASP1CYP1A2HIF1ACASP7
SCHEMBL22200816 0.93 ERN1 (0.38) USP2CASP1CYP1A2HIF1ACASP7
SCHEMBL22200603 0.90 ERN1 (0.43) USP2CASP1CYP1A2HIF1ACASP7
SCHEMBL22200594 0.89 RORC (0.34) USP2CASP1CYP1A2HIF1ACASP7
SCHEMBL22200549 0.88 ERN1 (0.37) USP2CASP1CYP1A2HIF1ACASP7
SCHEMBL22200568 0.85 ERN1 (0.41) ERN1
SCHEMBL22200612 0.85 RORC (0.35) USP2CASP1CYP1A2HIF1ACASP7
SCHEMBL25035661 0.84 ERN1 (0.48) USP2CASP1CYP1A2HIF1ACASP7
SCHEMBL22200719 0.83 ERN1 (0.42) USP2CASP1CYP1A2HIF1ACASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed